OBSN — Obseva SA Share News
0.000.00%
Last trade - 00:00- CH₣0.14m
- -CH₣2.20m
- $19.64m
Switzerland's Obseva eyes China re-start for fertility drug that failed trial
Street View: Wait for more news on ObsEva's heavy menstrual bleeding drug
Brief: Obseva: Positive Results From Uterine Fibroids Phase 3 Study Of Linzagolix
Swiss stocks - Factors to watch on November 8
ObsEva plunges on discontinuing fertility drug after trial failure
ObsEva IVF nolasiban drug flops in key European trial
Brief: ObsEva Q3 Net Loss Of $27.6 Mln
Swiss stocks - Factors to watch on September 12
Brief: ObsEva Announces New Composition Of Its Executive Committee
Brief: Obseva SA Files For Mixed Shelf Of Upto $250 Million
Brief: Obseva To Increase Issued Share Capital
Swiss stocks - Factors to watch on July 1
Brief: Obseva Appoints Dr. Elizabeth Garner As Chief Medical Officer
Brief: Obseva Progressing Toward U.S. Phase 3 Trial For Nolasiban In IVF Following Recent FDA Meeting
Myovant: Drops on 'unimpressive' efficacy data on uterine fibroid therapy